Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long‐Term Follow‐Up From the CAP Randomised Trial
International Journal of Cancer · 01.09.2026 · 159 (5) · 1196-1203
DOI: 10.1002/ijc.70492 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Cancer, online erschienen am 22.04.2026. Verfasst von Adam R Brentnall und 5 weiteren Autor:innen. Beteiligte Einrichtung: Wolfson Institute of Population Health, Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Overdiagnosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Cancer Research UK.
Abstract (Originalsprache)
Prostate cancer overdiagnosis is detection of prostate cancer through PSA testing that otherwise would not have been diagnosed within the patient's lifetime. It is a major concern to policymakers due to its impact on quality of life. We used long‐term follow‐up data from the CAP randomised trial of a one‐off screen, and English male competing mortality rates (2021–23), to estimate the impact of age on excess prostate cancer incidence within 15 years (‘overdiagnosis’) using competing‐risks methods. In total, 2249 (1.19%) of 189,386 men invited for a PSA test in CAP had cancer detected at the one‐off screen. Prostate cancer cumulative incidence at 15 years was 7.08% (95% CI 6.95%–7.21%) in those invited to screening, compared with 6.94% (95% CI 6.82%–7.06%) in the control arm; an absolute excess incidence difference of 0.14% (95% CI −0.04% to 0.37%). Excess net incidence to 15 years was 0.14/1.19 = 11.7% (95% CI 0.0%–26.7%) of cases detected at a single prevalent screen. Accounting for competing mortality, men diagnosed at screening aged 50 years were projected to have a 16% chance the cancer would not have been detected within 15 years, rising to 32% if detected at screening aged 70 years and 58% aged 80 years. Thus, prostate cancer overdiagnosis rises substantially with age due to competing mortality, and is relatively low for younger men. Accordingly, policies that enable opportunistic testing should be re‐examined in settings where they have led to high rates of screening in older men.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
- Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Adam R Brentnall, Matejka Rebolj, Andrew J Vickers
Förderung
- NCI NIH HHS
- NIH HHS
- Cancer Research UK
- National Institutes of Health
Zitieren
APA
Brentnall, A. R., Rebolj, M., Sasieni, P., Funston, G., Gabe, R., & Vickers, A. J. (2026). Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long‐Term Follow‐Up From the CAP Randomised Trial. International Journal of Cancer, 159(5), 1196-1203. https://doi.org/10.1002/ijc.70492
Vancouver
Brentnall AR, Rebolj M, Sasieni P, Funston G, Gabe R, Vickers AJ. Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long‐Term Follow‐Up From the CAP Randomised Trial. International Journal of Cancer. 2026;159(5):1196-1203. doi:10.1002/ijc.70492
BibTeX
@article{Brentnall2026,
author = {Brentnall, Adam R and Rebolj, Matejka and Sasieni, Peter and Funston, Garth and Gabe, Rhian and Vickers, Andrew J},
title = {Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long‐Term Follow‐Up From the CAP Randomised Trial},
journal = {International Journal of Cancer},
year = {2026},
volume = {159},
number = {5},
pages = {1196--1203},
doi = {10.1002/ijc.70492}
}
EUVIMED